Medicare rejected a controversial Alzheimer's drug. Participants still ended up paying for it.

Oct 24, 2022
Medicare raised premiums late last year in preparation to cover the drug Aduhelm. Ultimately, Medicare rejected coverage of the drug, with limited exceptions.
Biogen initially priced its Alzheimer’s treatment drug at $56,000 a year. That figure was factored in when Medicare set Part B premiums late last year.
Dominick Reuter/AFP via Getty Images

As the population ages, the costs of dementia will climb, report finds

From medical costs to the value of unpaid caregiving, dementia is getting more expensive for families.
From medical costs to the value of unpaid caregiving, dementia is getting more expensive for families.
Thomas Kienzle/AFP/Getty Images

Who will end up paying the price for Biogen's new Alzheimer's drug?

Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images

How undiagnosed Alzheimer's can impact personal finances

Oct 25, 2019
Early-stage Alzheimer's linked to unwise financial decision-making and vulnerability to financial exploitation.
Christopher Furlong/Getty Images

The cartoonist drawing comics about his mother's Alzheimer's

Sep 26, 2019
Ted Rall's new cartoons tackle the isolation and financial stress of family caregiving.
Courtesy of Ted Rall

Could adult daycare centers be one solution to providing lower cost care for Alzheimer's patients?

Dec 14, 2018
Lower cost adult daycare programs could be one solution for affordable care for Americans living with Alzheimer's.
A patient affected by Alzheimer's disease gestures as he attends a special therapeutic session. 

Bill Gates says big data can help solve the Alzheimer's puzzle

Nov 13, 2017
The disease affects over 5 million Americans and has no cure.
Bill Gates is trying to help find a cure for Alzheimer's disease.
Axel Schmidt - Pool/Getty Images

For public good, not for profit.

Why 23andMe wants your genetic data

Apr 19, 2017
CEO Anne Wojcicki hopes the collective power of health information will advance research.
"In some ways the world is just starting, but in some ways I think we've really driven a lot of change," said 23andMe CEO Anne Wojcicki.
Kimberly White/Getty Images for Vanity Fair

FDA clears 23andMe to sell genetics tests for diseases

Apr 10, 2017
Consumers can get information to help them determine if they are at risk of developing Parkinson’s, Alzheimer’s and other diseases.
Anne Wojcicki is co-founder and CEO of 23andMe, a company that makes home DNA testing kits.
Photo by Brad Barket/Getty Images for Fast Company

How Minnesota's supporting people with Alzheimer's

Nov 30, 2015
A statewide program is training businesses how to deal with people with dementia.